SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 262.78 |
| Enterprise Value ($M) | 196.15 |
| Book Value ($M) | 137.41 |
| Book Value / Share | 9.25 |
| Price / Book | 1.91 |
| NCAV ($M) | 116.94 |
| NCAV / Share | 7.87 |
| Price / NCAV | 2.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.35 |
| Return on Assets (ROA) | -0.24 |
| Return on Equity (ROE) | -0.29 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.09 |
| Current Ratio | 9.09 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 143.65 |
| Assets | 164.12 |
| Liabilities | 26.71 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Redmile Group, LLC | 9.90 | 40.89 | |
| 13G/A | Great Point Partners Llc | 2.98 | -55.91 | |
| 13G/A | Rtw Investments, Lp | 9.99 | 32.03 | |
| 13G/A | Janus Henderson Group Plc | 0.00 | -100.00 | |
| 13G/A | Casdin Capital, LLC | 8.70 | 26.42 | |
| 13G | Commodore Capital Lp | 5.40 | ||
| 13G/A | Samsara BioCapital, L.P. | 11.60 | 33.88 | |
| 13G/A | Cormorant Asset Management, LP | 0.83 | -85.61 | |
| 13G | Fmr Llc | 5.63 | ||
| 13G | EcoR1 Capital, LLC | 9.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 49,115 | 153,058 | 32.09 | |
| 15,541 | 45,904 | 33.86 | |
| 73,801 | 190,556 | 38.73 | |
| 33,714 | 114,783 | 29.37 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NAII – Natural Alternatives International, Inc. | NAMS – NewAmsterdam Pharma Company N.V. |
| NEUP – Neuphoria Therapeutics Inc. | NKGN – NKGen Biotech, Inc. |
| NRIX – Nurix Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io